Consumer device launched to monitor mental acuity

Neurolign, a specialist in clinical eye tracking and neuro-functional diagnostic testing, has launched NeurolignFit – a consumer health and wellness device that uses professional eye-tracking technology to allow users to track, understand, and improve their overall mental acuity from home. 

Neurolign stands at the forefront of brain health technology, and the release of NeurolignFit is a landmark in the company’s mission to bring neurological training into the home and make brain health a key part of everyday wellness practices.

Eugene Melnyd, chairman and CEO of Neurolign, said: “The brain, just like any other part of the human body, needs to be exercised and cared for, and with the ongoing COVID-19 pandemic reinvigorating public dialogue around wellness, a product like NeurolignFit has never been more prescient. Until now, the research-backed benefits of eye-based neuro-functional evaluation have been out of reach for the public. By putting the power of this technology into an intuitive, gamified consumer device, Neurolign is hoping to change the way people think about and improve their brain health and wellness.”

The platform consists of an easy-to-use handheld device and a mobile app, which together utilise clinical-grade eye-tracking technology to facilitate a series of rapid, non-invasive neurological assessments. The data from these tests is then run through an algorithm that creates an ongoing report of users’ latest brain performance in three key areas – mental sharpness, focus, and movement – and offers users a series of gamified eye-based exercises to train those three areas over time.

The technology underpinning NeurolignFit has been in development for over 30 years and is implemented in a range of medical fields, thanks to its ability to detect the eye movements associated with over 200 different diseases and medical conditions. Traditionally, this technology has been confined to bulky and expensive devices that can only be utilised in a professional setting, thus relegated to research labs and clinical facilities. 

Dr. Alex Kiderman, Neurolign’s VP of technology development, said: “Neurolign’s eye-tracking technology is backed with 30 patents, 60+ research citations and eight clinical studies in the past year alone, alongside extensive peer consultation. NeurolignFit is the culmination of our efforts to consolidate the tremendous power of clinical eye-tracking technology into a consumer-friendly platform. The ability to put brain health tools into the hands of consumers marks a turning point for wellness technology writ large.”